In last trading session, Sage Therapeutics Inc (NASDAQ:SAGE) saw 0.33 million shares changing hands with its beta currently measuring 0.88. Company’s recent per share price level of $5.62 trading at $0.07 or 1.26% at ring of the bell on the day assigns it a market valuation of $343.79M. That closing price of SAGE’s stock is at a discount of -402.85% from its 52-week high price of $28.26 and is indicating a premium of 17.79% from its 52-week low price of $4.62. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.01 million shares which gives us an average trading volume of 729.86K if we extend that period to 3-months.
For Sage Therapeutics Inc (SAGE), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 2.85. Splitting up the data highlights that, out of 8 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 4 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -1.47 in the current quarter.
Sage Therapeutics Inc (NASDAQ:SAGE) trade information
Upright in the green during last session for gaining 1.26%, in the last five days SAGE remained trading in the green while hitting it’s week-highest on Wednesday, 11/27/24 when the stock touched $5.62 price level, adding 4.91% to its value on the day. Sage Therapeutics Inc’s shares saw a change of -74.07% in year-to-date performance and have moved 15.88% in past 5-day. Sage Therapeutics Inc (NASDAQ:SAGE) showed a performance of -12.73% in past 30-days. Number of shares sold short was 6.41 million shares which calculate 8.37 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 28 to the stock, which implies a rise of 79.93% to its current value. Analysts have been projecting 4 as a low price target for the stock while placing it at a high target of 105. It follows that stock’s current price would jump 28.83% in reaching the projected high whereas dropping to the targeted low would mean a gain of 28.83% for stock’s current value.
Sage Therapeutics Inc (SAGE) estimates and forecasts
Statistics highlight that Sage Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -49.41% of value to its shares in past 6 months, showing an annual growth rate of 27.85% while that of industry is 16.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to fall -51.09% from the last financial year’s standing.
17 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 14.16M for the same. And 6 analysts are in estimates of company making revenue of 16.52M in the next quarter. Company posted 77.97M and 7.9M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -2.28% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 28.02% while estimates for its earnings growth in next 5 years are of 16.80%.
Sage Therapeutics Inc (NASDAQ:SAGE)’s Major holders
Insiders are in possession of 11.92% of company’s total shares while institution are holding 86.44 percent of that, with stock having share float percentage of 98.13%. Investors also watch the number of corporate investors in a company very closely, which is 86.44% institutions for Sage Therapeutics Inc that are currently holding shares of the company. VANGUARD GROUP INC is the top institutional holder at SAGE for having 6.42 million shares of worth $69.68 million. And as of 2024-06-30, it was holding 10.6696 of the company’s outstanding shares.
The second largest institutional holder is FMR LLC, which was holding about 5.82 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.6836 of outstanding shares, having a total worth of $63.24 million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Fidelity Growth Company Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.71 shares of worth $9.38 million or 2.80% of the total outstanding shares. The later fund manager was in possession of 1.6 shares on Sep 30, 2024 , making its stake of worth around $8.76 million in the company or a holder of 2.62% of company’s stock.
